.jpg)
.png)
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved evolocumab for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Evolocumab is produced by Amgen, and known by the brand name Repatha.
News Stories
Following a June 2015 recommendation by the U.S Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee, the FDA has approved alirocumab for patients on maximally tolerated statin therapy with heterozygous familial hypercholesterolemia (HeFH) or with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol. Alirocumab is produced by Sanofi and Regeneron, and known by the brand name Praluent.
Name: Top Stories
The 2014 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw another increase — from 3.587 (2013) to 3.904 (2014). The Journal is now ranked 44th out of 254 journals in its category (pharmacology and pharmacy). The Thomson-Reuters Impact Factor represents the ratio of articles quoted in other scientific publications compared to the total qualifying articles during the years 2012 and 2013.
Name: NLA News